Accordingly, these findings suggested that targeting phospho-STAT3(Tyr705) and phospho-STAT5(Tyr694) may be a potential novel therapy strategy for IDH2/R140Q-mutated AML. Here, STAT3 is linked to acute myeloid leukemia.